Axicabtagene ciloleucel clinical trials
Also written Yescarta® and KTE-C19.
How each study uses axicabtagene ciloleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the axicabtagene ciloleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Oct 2017 · Yescarta · BLA 125643 (FDA, Purple Book)
- European Union
- 23 Aug 2018 · Yescarta · EMEA/H/C/004480 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 16
Kite, A Gilead Company (10) · Ruijin Hospital (2) · M.D. Anderson Cancer Center (2) · Stanford University (1) · Dana-Farber Cancer Institute (1) · The Lymphoma Academic Research Organisation (1) · Masonic Cancer Center, University of Minnesota (1) · Vanderbilt-Ingram Cancer Center (1)
Often tested with
Tested in the same studies.
Fludarabine (3) · Cyclophosphamide (3) · Tisagenlecleucel (2) · Lisocabtagene maraleucel (2) · Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753 (1) · Brexucabtagene autoleucel (1) · Idecabtagene vicleucel (1) · Rituximab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test axicabtagene ciloleucel.
- Dec 2026Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular LymphomaPhase 2 · The First Affiliated Hospital of Xiamen University
- Jan 2027Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaPhase 2 · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Jul 2027A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaPhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses axicabtagene ciloleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 26
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06213311Written as Axi-cel
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2SWOG Cancer Research NetworkNCT05633615Written as Axicabtagene Ciloleucel
- A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06043323Written as Axicabtagene Ciloleucel
- Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaRecruitingPhase 1AIDS Malignancy ConsortiumNCT05077527Written as Axicabtagene Ciloleucel
- CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.RecruitingPhase 2Zhejiang Cancer HospitalNCT07538635Written as Axicabtagene Ciloleucel
- Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T CellsRecruitingPhase 2City of Hope Medical CenterNCT07042438Written as Axicabtagene Ciloleucel
- Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaRecruitingPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT07254754Written as Axicabtagene Ciloleucel
- Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell LymphomaNot yet recruitingNot applicableRuijin HospitalNCT06935136Written as Axicabtagene Ciloleucel
- Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular LymphomaRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06826118Written as Axicabtagene Ciloleucel
- Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell LymphomaRecruitingPhase 4Zhengzhou UniversityNCT06609304Written as Axicabtagene Ciloleucel
- Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell LymphomaCompletedPhase 2Kite, A Gilead CompanyNCT05459571Written as Axicabtagene Ciloleucel
- Axicabtagene Ciloleucel Reinfusion(Axi-Cel-2) in Relapsed/Refractory 2nd Line High-Risk NHLActive, not recruitingPhase 1Stanford UniversityNCT05794958Written as Axicabtagene Ciloleucel
- Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyActive, not recruitingPhase 3Kite, A Gilead CompanyNCT07479797Written as Axicabtagene Ciloleucel
- Axi-cel in CNS LymphomaActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT04608487Written as Axicabtagene Ciloleucel
- Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell LymphomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT05605899Written as Axicabtagene Ciloleucel
- Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell TransplantationActive, not recruitingPhase 2The Lymphoma Academic Research OrganisationNCT04531046Written as axicabtagene ciloleucel
- MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03642626Written as YESCARTA
- A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin LymphomaCompletedPhase 2Kite, A Gilead CompanyNCT03105336Written as Axicabtagene ciloleucel
- Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedPhase 3Kite, A Gilead CompanyNCT03391466Written as Axicabtagene Ciloleucel
- Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT05371093Written as Axicabtagene Ciloleucel
See all 26 studies that test axicabtagene ciloleucel →
Given beside what is tested · 15 — axicabtagene ciloleucel is usual care or a partner of the new treatment
- Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2University of Michigan Rogel Cancer CenterNCT07932730Written as Axicabtagene Ciloleucel
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT07892027Written as Axicabtagene Ciloleucel
- Emapalumab Prevention of CAR-T Cell Associated ToxicitiesRecruitingPhase 2Marcela V. Maus, M.D.,Ph.D.NCT06550141Written as Axicabtagene Ciloleucel
- Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT07763210Written as Axicabtagene Ciloleucel
- Glofitamab Combined With CAR-T Therapy in R/R DLBCLNot yet recruitingPhase 2Ruijin HospitalNCT07326371Written as Axicabtagene Ciloleucel
- Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedPhase 1/2Masonic Cancer Center, University of MinnesotaNCT04855253Written as Axicabtagene Ciloleucel
- Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedPhase 1NeoImmuneTechNCT05075603Written as Axicabtagene ciloleucel
- Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaActive, not recruitingPhase 1/2University of WashingtonNCT04257578Written as Axicabtagene Ciloleucel
- Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)CompletedPhase 2Kite, A Gilead CompanyNCT02601313Written as Axicabtagene Ciloleucel
- Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell LymphomaTerminatedPhase 2Jonsson Comprehensive Cancer CenterNCT04205838Written as Axicabtagene Ciloleucel
- A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated NeurotoxicityCompletedPhase 2Marcela V. Maus, M.D.,Ph.D.NCT04150913Written as Axicabtagene Ciloleucel
- Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell LymphomaCompletedPhase 2M.D. Anderson Cancer CenterNCT04432506Written as Axicabtagene Ciloleucel
- Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell LymphomaTerminatedPhase 1Kite, A Gilead CompanyNCT03704298Written as Axicabtagene Ciloleucel
- Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaCompletedPhase 1/2Kite, A Gilead CompanyNCT02348216Written as Axicabtagene Ciloleucel
- A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell TherapyCompletedPhase 2Incyte CorporationNCT04071366Written as Yescarta
As the comparator · 2 — what is tested is compared with axicabtagene ciloleucel
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyRecruitingPhase 3Lyell Immunopharma, Inc.NCT07188558Written as axicabtagene ciloleucel
- Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCLActive, not recruitingPhase 2University Medical Center GroningenNCT05641428Written as Axi-cel
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Codes
What other systems call axicabtagene ciloleucel · ClinicalTrials.gg INT001010
- MeSH (NLM) C000629083axicabtagene ciloleucelConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) U2I8T43Y7RAXICABTAGENE CILOLEUCELConfirmed FDA, NLM, Wikidata
- RxNorm 1987398Confirmed FDA, Wikidata
- Wikidata Q30314851axicabtagene ciloleucelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C120309Axicabtagene CiloleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629083 | axicabtagene ciloleucel | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | U2I8T43Y7R | AXICABTAGENE CILOLEUCEL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1987398 | — | Confirmed FDA, Wikidata |
| Wikidata | Q30314851 | axicabtagene ciloleucel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C120309 | Axicabtagene Ciloleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.